CTRI/2021/03/031895已完成未知
AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-TREATMENT, TWO-PERIOD, TWO-WAY CROSSOVER, RELATIVE BIOAVAILABILITY STUDY OF TWO DIFFERENT FORMULATONS OF CURCUMIN 10 MG ORALLY SOLUBLE TABLET MANUFACTURED BY KMS HEALTH CENTER PVT. LTD., EAST TAMBARAM, SELAIYUR, CHENNAI AND CURCUNEX G 5 MG MANUFACTURED BY YEUS LIFESCIENCE PVT LTD, A-10, ART GOLD HOUSE, LBS MARG, MUMBAI 400 070. IN HEALTHY, ADULT, HUMAN, MALE SUBJECTS UNDER FASTING CONDITIONS.
KMS Health Center Pvt Ltd0 个研究点目标入组 3 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 3
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Healthy, adult, human male volunteers of age between 18-45 years
排除标准
- •1.Evidence of allergy or known hypersensitivity to Curcumin and its inactive ingredients.
- •2.Subjects with hepatic encephalopathy, cholestasis, myasthenia, pre-existing liver disease, alcohol abuse and recently overcome or active existing tinnitus.
- •3.Subjects with acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.
- •4.Any major illness in the last three months or any significant ongoing chronic medical illness.
- •5.Any disease or condition which might compromise the hemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, musculoskeletal, respiratory, central nervous system, diabetes, psychosis or any other body system.
- •6.History of drug abuse within 03 months (including benzodiazepines, opioids, cocaine, barbiturates, THC and amphetamine etc.).
- •7.History of alcohol addiction or abuse.
- •8.History of difficulty in swallowing.
- •9.History of difficulty in accessibility of veins.
- •10.Any blood donation / excess blood loss within 90 days of check-in.
- •11.Subject who had participated in any other study within the 90 days of study check-in.
- •12.Consumption of caffeine and /or Xanthine containing products (i.e. coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) and tobacco containing products for at least 24.00 hours prior to check-in and throughout the entire study.
- •13.Consumption of alcohol and its products, grapefruit and/ or its juice and poppy containing foods within 48.00 hours prior to clinic admission and throughout the entire study.
- •14.Use of any prescribed medication within 14 days and any over the counter medicinal products, herbal medications, etc. within 07 days prior to study check in and throughout the study.
研究者
相似试验
已完成
不适用
AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-TREATMENT (FED VS FASTING), TWO-PERIOD, TWO-SEQUENCE CROSSOVER STUDY TO ASSESS THE EFFECT OF FOOD ON SODIUM OXYBATE FOR EXTENDED RELEASE ORAL SUPENSION (FT218) FORMULATION ADMINISTRERED AT 6 G IN HEALTHY VOLUNTEERSNL-OMON44554Flamel Ireland Limited (Ltd) trading under the business name Avadel Ireland16
尚未招募
不适用
A CROSSOVER, ORAL BIOAVAILABILITY STUDY OF INVESTIGATIONAL PRODUCT (ZEAL VITAMIN C) OF PLANT LIPIDS, AND REFERENCE PRODUCT (VITAMIN C) OF PLANT LIPIDS IN HEALTHY, ADULT, HUMAN SUBJECTS UNDER FASTING CONDITIONS.CTRI/2019/07/020159Aurea Biolabs P Ltd
已完成
不适用
A RANDOMIZED, TWO-PERIOD, OPEN-LABEL, SINGLE DOSE CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF AQX-1125 IMMEDIATE RELEASE TABLETS AND CAPSULES IN HEALTHY VOLUNTEERSInterstitial Cystitis/Bladder Pain Syndrome (IC/BPS)10004994NL-OMON42576Aquinox Pharmaceuticals (Canada) Inc.18
进行中（未招募）
1 期
AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERSIntramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.CTIS2023-509399-40-00aboratorio Italiano Biochimico Farmaceutico Lisapharma S.p.A.30
已完成
不适用
A clinical trial to evaluate the bioequivalenc of new formulation of aliskiren (SPP100) 300 mg tablet administered after light meal.CTRI/2012/04/002573ovartis Healthcare Private Limited136